Dynamic Biosystems Snags Nearly CNY 100 Mn in Series A+

Healthcare Author: Mianmian Wang Feb 06, 2023 07:25 PM (GMT+8)

Dynamic Biosystems is a single cell and space multi-omics technology platform enterprise. The company focuses on exploring the huge potential in the fields of precision medicine of tumor, eugenics and fertility, and drug discovery, and is committed to promoting precision medicine to the era of single cell and space omics, helping life science and clinical medicine.


Dynamic Biosystems announced the completion of a Series A+ financing round worth nearly 100 million CNY. 

The round was led by Longpan Investment, followed by Ruihua Capital and the existing investor Guan Ya Investment continued. The funding will be used to strengthen the company's positioning and leadership in clinical applications of single-cell spatial omics. 

Dynamic Biosystems has the leading underlying technology and original ability in the field of single-cell spatial omics, which is the most advanced technology in the world. 

The founder, chairman and chief scientist of the company, Professor Yang Chaoyong, is an internationally renowned expert in microfluidic and single-cell, and has undertaken a number of national key projects, major project subjects and national major scientific research instrument projects. More than 40 patents for single cell recognition, enrichment and sequencing have been approved. Professor Rongqin Ke, Vice President of the Company and Chief Scientist of in Situ Technology, is the first author of the first paper on in situ sequencing technology in Nature Methods. He is one of the inventors of in situ sequencing technology in the world. He used to be a senior scientist of Complete Genomics and has a profound knowledge of sequencing related underlying technologies.